Advertisement

Where Will Biogen Be in 1 Year?

Where Will Biogen Be in 1 Year?

Biogen (NASDAQ: BIIB) stock has been on fire for the past month with a stunning gain of 46%, adding over $20 billion to its market cap. The biotech has dazzled investors and patients alike after receiving a conditional approval from the U.S. Food and Drug Administration (FDA) for Aduhelm. The drug targets Alzheimer's disease and is the first in 20 years to receive regulatory clearance for the indication.